Full history for every metric is available with a Kvantra account
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €bn | 37.4 | 39.2 | 40.3 | 41.1 | 44.3 | 46.7 | 48.9 | 48.9 |
| Operating profit | €bn | 9.6 | 10.1 | ||||||
| Net profit | €bn | 12.3 | 6.2 | 8.4 | 5.4 | 5.6 | 7.8 | 4.0 | 10.3 |
| EPS reported | € | 6.40 | 3.24 | ||||||
| Operating cashflow per share | € | 8.81 | 14.43 | ||||||
| Capex per share | € | 1.44 | 0.66 | ||||||
| FCF per share | € | 7.36 | 13.77 | ||||||
| Free cash flow | €bn | 9.0 | 16.5 | ||||||
| Net debt | €bn | 10.9 | 15.3 | ||||||
| Book value equity | €bn | 71.4 | 69.2 | ||||||
| Book value per share | € | 58.49 | 57.84 | ||||||
| Number of shares | m | 1,220.4 | 1,196.6 | ||||||
| DPS (TTM paid) | € | 4.12 | 4.12 |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 12.92 | 22.10 | ||||||
| P/B LTM | x | 1.41 | 1.23 | ||||||
| P/S LTM | x | 2.16 | 1.74 | ||||||
| P/FCF LTM | x | 11.23 | 5.16 | ||||||
| EV/EBITDA LTM | x | 9.13 | 12.16 | ||||||
| EV/Sales LTM | x | 2.44 | 2.05 | ||||||
| Earnings Yield LTM | % | 7.74% | 4.52% | ||||||
| FCF Yield | % | 8.90% | 19.38% | ||||||
| Quality | |||||||||
| ROE | % | 10.95% | 5.52% | ||||||
| ROIC | % | 7.70% | 7.41% | ||||||
| Operating margin | % | 20.54% | 20.58% | ||||||
| Gross margin | % | 72.07% | 72.77% | ||||||
| FCF/Sales | % | 19.24% | 33.68% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +45.79% | -57.79% | ||||||
| Sales Growth YoY | % | +5.49% | +4.26% | ||||||
| Net Income Growth YoY | % | +40.52% | -57.49% | ||||||
| FCF Growth | % | +52.70% | +36.87% | ||||||
| Operating Profit Growth | % | -33.58% | +14.87% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 4.73% | 5.75% | ||||||
| Dividend Growth | % | +5.10% | +5.10% | ||||||
| Payout Ratio | % | 61.10% | 125.38% | ||||||
| FCF/Debt | x | 0.44 | 0.70 | ||||||
| Net Debt/EBITDA | x | 1.04 | 2.09 | ||||||
| EBIT/Net interest | x | 15.33 | 13.79 | ||||||
| Net debt/market cap | % | 10.83% | 18.02% | ||||||
| Net debt/Equity | x | 0.15 | 0.22 | ||||||
| Gross debt/equity | x | 0.28 | 0.34 | ||||||
ETFs that hold Sanofi
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| Amundi CAC 40 UCITS ETF Acc | CACC.PA | 8 | 4.77% |
| iShares MSCI EMU CTB Enhanced ESG UCITS ETF | EDM4.DE | 9 | 1.97% |
| Amundi S&P Eurozone Climate Paris Aligned UCITS ETF Acc | EPAB.PA | 7 | 3.25% |
| iShares Edge MSCI Europe Value Factor UCITS ETF | IEVL.L | 2 | 4.08% |
| State Street SPDR S&P Euro Dividend Aristocrats UCITS ETF (Dist) | SPYW.DE | 9 | 3.13% |
| WisdomTree Europe Hedged Equity Fund | HEDJ | 6 | 3.35% |
| iShares International Dividend Growth ETF | IGRO | 8 | 2.20% |
| Amundi STOXX Europe 600 Healthcare UCITS ETF Acc | HLT.PA | 4 | 4.53% |
| iShares MSCI Europe Health Care Sector UCITS ETF | ESIH.DE | 6 | 5.12% |
| Invesco International Dividend Achievers ETF | PID | 7 | 2.91% |
Funds with Sanofi among their ten largest holdings, largest fund first.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Sanofi is a global healthcare enterprise dedicated to the research, development, manufacturing, and commercialization of therapeutic solutions across the United States, Europe, and other international markets. Its business is structured into three primary divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. The Pharmaceuticals segment delivers specialized treatments, encompassing human monoclonal antibodies and therapies for a range of conditions such as multiple sclerosis, neurological disorders, various inflammatory and immunological diseases, rare disorders, oncology, and rare blood conditions. This division also provides medications for diabetes, cardiovascular health, and a portfolio of established prescription drugs. Through its Vaccines division, Sanofi supplies crucial immunizations, including pediatric vaccines for diseases like poliomyelitis, pertussis, and Hib, alongside adult vaccines addressing influenza, booster needs, meningitis, and those required for travel or endemic regions. The Consumer Healthcare portfolio features over-the-counter remedies for common ailments such as allergies, coughs and colds, and pain relief. It also includes products for liver care, general physical and mental wellness, probiotics, digestive health, and nutritional support. Additionally, this segment offers personal care items like daily body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and powders for eczema. Sanofi maintains an active pipeline with numerous pharmaceutical products and vaccines currently undergoing various stages of development. The company has forged strategic alliances, including a collaboration with GlaxoSmithKline for the development of a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine aimed at advancing immunology and inflammation knowledge, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company operated as Sanofi-Aventis before rebranding to Sanofi in May 2011.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| Amundi CAC 40 UCITS ETF Acc | CACC.PA | 8 | 4.77% |
| iShares MSCI EMU CTB Enhanced ESG UCITS ETF | EDM4.DE | 9 | 1.97% |
| Amundi S&P Eurozone Climate Paris Aligned UCITS ETF Acc | EPAB.PA | 7 | 3.25% |
| iShares Edge MSCI Europe Value Factor UCITS ETF | IEVL.L | 2 | 4.08% |
| State Street SPDR S&P Euro Dividend Aristocrats UCITS ETF (Dist) | SPYW.DE | 9 | 3.13% |
| WisdomTree Europe Hedged Equity Fund | HEDJ | 6 | 3.35% |
| iShares International Dividend Growth ETF | IGRO | 8 | 2.20% |
| Amundi STOXX Europe 600 Healthcare UCITS ETF Acc | HLT.PA | 4 | 4.53% |
| iShares MSCI Europe Health Care Sector UCITS ETF | ESIH.DE | 6 | 5.12% |
| Invesco International Dividend Achievers ETF | PID | 7 | 2.91% |
Funds with Sanofi among their ten largest holdings, largest fund first.
Based on consensus from external analysts. Not Kvantra's opinion.
Sanofi is a global healthcare enterprise dedicated to the research, development, manufacturing, and commercialization of therapeutic solutions across the United States, Europe, and other international markets. Its business is structured into three primary divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. The Pharmaceuticals segment delivers specialized treatments, encompassing human monoclonal antibodies and therapies for a range of conditions such as multiple sclerosis, neurological disorders, various inflammatory and immunological diseases, rare disorders, oncology, and rare blood conditions. This division also provides medications for diabetes, cardiovascular health, and a portfolio of established prescription drugs. Through its Vaccines division, Sanofi supplies crucial immunizations, including pediatric vaccines for diseases like poliomyelitis, pertussis, and Hib, alongside adult vaccines addressing influenza, booster needs, meningitis, and those required for travel or endemic regions. The Consumer Healthcare portfolio features over-the-counter remedies for common ailments such as allergies, coughs and colds, and pain relief. It also includes products for liver care, general physical and mental wellness, probiotics, digestive health, and nutritional support. Additionally, this segment offers personal care items like daily body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and powders for eczema. Sanofi maintains an active pipeline with numerous pharmaceutical products and vaccines currently undergoing various stages of development. The company has forged strategic alliances, including a collaboration with GlaxoSmithKline for the development of a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine aimed at advancing immunology and inflammation knowledge, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company operated as Sanofi-Aventis before rebranding to Sanofi in May 2011.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free